Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.
Neuropathy treatment runs in two gears: treat the cause and treat the symptoms. Symptomatic relief alone, without addressing etiology, leaves the disease advancing underneath.
Treating the cause
Metabolic and endocrine causes come first because they are common. Glycemic control slows diabetic polyneuropathy but does not reverse established damage, and blood pressure, lipid, and smoking control matter equally. Dialysis and transplantation address uremic disease, and hormone replacement reverses hypothyroid neuropathy.
Toxic and deficiency causes require removing the trigger: alcohol, offending drugs, solvents, and dose adjustment of chemotherapy where possible. Deficient vitamins are replaced, with one paradox to remember: vitamin B6 deficiency causes neuropathy, but excess B6 causes a sensory ataxia of its own, so supplementation is dosed rather than open-ended.
Infections are treated directly: antibiotics for Lyme disease and leprosy multidrug regimens, antivirals for HIV, and hepatitis C therapy, which also addresses cryoglobulinemic disease.
Immune causes follow disease-specific protocols. Guillain-Barre syndrome receives IV immunoglobulin or plasma exchange, never steroids alone; the full protocol sits under Guillain-Barre syndrome (/notes/neurology/neuropathies-guillain-barre-syndrome/). CIDP answers to steroids, immunoglobulin, and plasma exchange, often as maintenance. Vasculitis needs steroids plus immunosuppression such as cyclophosphamide in severe disease. Paraneoplastic disease is treated through the tumor with plasma exchange as adjunct.
Hereditary disease is mostly supportive. Transthyretin amyloidosis is the exception with real options: historical liver transplantation plus current stabilizer, gene-silencing, and antisense therapies. Charcot-Marie-Tooth disease is managed with physiotherapy and orthotics, and hereditary pressure-palsy disease by avoiding pressure, since neither answers to immunotherapy.
| Category | Condition | Treatment direction |
|---|---|---|
| Hereditary | Transthyretin amyloidosis | Transplantation history; stabilizer, silencing, and antisense options |
| Hereditary | Charcot-Marie-Tooth disease | Physiotherapy and orthotics |
| Endocrine | Diabetes, uremia, hypothyroidism | Glycemic and vascular control; dialysis or transplant; hormone replacement |
| Toxic or deficiency | Alcohol, drugs, solvents, vitamin deficiency | Remove exposure; replace B1, B6, B12, folate, E |
| Infectious | HIV, hepatitis C, leprosy, Lyme disease | Antiretrovirals; hepatitis therapy; multidrug antibiotics |
| Inflammatory | CIDP, IgM gammopathy, vasculitis, paraneoplastic | Steroids, immunoglobulin, or exchange; rituximab or exchange for IgM disease; immunosuppression; tumor treatment |
Treating neuropathic pain
Neuropathic pain comes from lesioned or dysfunctional somatosensory pathways and does not answer to ordinary analgesics the way nociceptive pain does. Current guidance recommends amitriptyline, duloxetine, gabapentin, or pregabalin as initial options, chosen by comorbidity: duloxetine where depression coexists, pregabalin where anxiety dominates, amitriptyline where insomnia needs covering and anticholinergic effects are tolerable.
Representative adult ranges from published reviews are amitriptyline around 75 mg daily, duloxetine 60 mg daily, gabapentin titrated up to about 3600 mg daily in divided doses, and pregabalin 300 to 600 mg daily in divided doses. These are starting points for individual titration, not fixed targets, and roughly a third to two-thirds of patients respond depending on drug and population. Non-response prompts switching or combining, commonly gabapentin with a tricyclic, with the predictable cost of added sedation. Tramadol or oxycodone enter only for refractory pain under time limits because of dependence risk. Throughout, pain control runs alongside the search for and treatment of the underlying cause.
Chemotherapy-induced disease
No proven pharmacological prevention exists. The most effective intervention is dose reduction or schedule change, which matters more because platinum damage can coast onward after the drug stops. Calcium and magnesium infusions have mixed evidence in oxaliplatin injury, and agents such as acetyl-L-carnitine remain investigational. Rehabilitation carries the practical load: balance training, orthotics for foot drop, and occupational support for hand function.
What not to do
Four negatives prevent real harm. Steroids have no place in multifocal motor neuropathy and may worsen it. Hereditary neuropathies do not answer to immunotherapy. Diabetic symmetric polyneuropathy is metabolic rather than immune-mediated, so immunotherapy is not its treatment. And stable, slowly progressive, sensory-predominant polyneuropathy in older patients with a negative basic workup does not warrant endless investigation; genetic testing may clarify atypical cases, but the yield of repeating the same search is low.
Evidence anchors
- NICE. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173): https://www.nice.org.uk/guidance/cg173
- NICE. Type 2 diabetes in adults: management (NG28): https://www.nice.org.uk/guidance/ng28
- NINDS. Peripheral Neuropathy: https://www.ninds.nih.gov/health-information/disorders/peripheral-neuropathy